Annual Report of the Perinatology Committee, Japan Society of Obstetrics and Gynecology, 2015: Proposal of urgent measures to reduce maternal deaths

J Obstet Gynaecol Res. 2017 Jan;43(1):5-7. doi: 10.1111/jog.13184.

Abstract

Perinatal care in Japan has progressed rapidly in recent decades, remarkably reducing maternal, perinatal and neonatal mortality rates. This is attributable not only to the sustained efforts and dedication of past obstetricians and midwives, but also to the collective results achieved by the Japan Society of Obstetrics and Gynecology and healthcare administration, including research on advanced medical care, education, medical care improvements and establishing perinatal care centers. Although the maternal mortality rate was in steady decline until 2007 (3.1/100 000 births), it repeatedly fluctuated thereafter, plateauing at 3.4 per 100 000 births in 2013 and 2.7 per 100 000 births in 2014. Thus, the Perinatology Committee has analyzed the current situation of maternal deaths and has proposed countermeasures to reduce such death. The items deliberated upon by related subcommittees in 2015 are presented herein. The addition of indications for 'fibrinogen concentrate', 'eptacog alfa' and approval of the PGE2 vaginal tablet for cervical ripening were discussed in the subcommittee for unapproved drug review. Thus, a request for approval for health insurance coverage was submitted to the 'Evaluation committee on unapproved or off-label drugs with high medical needs' of the Ministry of Health, Labour and Welfare. Maternal and late-maternal deaths from suicide during the 10 years from 2005 to 2014 in Tokyo's 23 wards were jointly examined with the Tokyo Medical Examiner's Office. The suicide rate in the 23 wards is very high, at 8.7 per 100 000 births. Thus, the subcommittee for the reduction of maternal death discussed countermeasures for the eradication of maternal death and maternal suicide and the revision of death certificates.

Publication types

  • Congress

MeSH terms

  • Cervical Ripening / drug effects
  • Dinoprostone / therapeutic use
  • Factor VIIa / therapeutic use
  • Female
  • Fibrinogen / therapeutic use
  • Humans
  • Insurance, Health
  • Japan
  • Maternal Death / prevention & control*
  • Maternal Death / statistics & numerical data
  • Maternal Mortality*
  • Perinatal Care / methods*
  • Perinatology*
  • Pregnancy
  • Recombinant Proteins / therapeutic use
  • Suicide Prevention

Substances

  • Recombinant Proteins
  • Fibrinogen
  • recombinant FVIIa
  • Factor VIIa
  • Dinoprostone